Aktis Oncology (NASDAQ:AKTS) Given Consensus Rating of “Moderate Buy” by Analysts

Aktis Oncology (NASDAQ:AKTS) has received an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $32.00.

AKTS has been the topic of several recent analyst reports. Leerink Partners initiated coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 target price on the stock. TD Cowen assumed coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They set a “buy” rating on the stock. HC Wainwright increased their target price on shares of Aktis Oncology from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Bank of America assumed coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 target price for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 target price for the company.

Aktis Oncology Stock Up 1.5%

NASDAQ AKTS opened at $20.74 on Friday. Aktis Oncology has a 52 week low of $14.72 and a 52 week high of $29.16. The stock has a 50-day moving average price of $18.82.

Aktis Oncology (NASDAQ:AKTS) last posted its earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The business had revenue of $1.87 million for the quarter. As a group, equities analysts expect that Aktis Oncology will post -1.56 earnings per share for the current year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.